Ergoteles’s Atara Biotherapeutics ATRA Stock Holding History

Ergoteles’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-813	Closed	-$32.7K	–	100
2023 Q2	$32.7K	Buy	+813	New	+$46K	﹤0.01%	969
2021 Q4	–	Sell	-839	Closed	-$376K	–	1228
2021 Q3	$376K	Buy	+839	New	+$301K	0.01%	701

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's ATRA Position: Q3 2023 in Review

Ergoteles sold out of Atara Biotherapeutics (ATRA) in Q3 2023, closing a stake of 813 shares — an estimated $32.7K sold.

Ergoteles first reported a position in ATRA in Q3 2021 and held it in 2 quarters. The position peaked at $376K in Q3 2021. 109 funds tracked by Wall St. Rank hold ATRA as of Q3 2023.

Ergoteles reported no remaining Atara Biotherapeutics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 813 Atara Biotherapeutics shares in Q3 2023, an estimated $32.7K.
Ergoteles first reported a position in Atara Biotherapeutics in Q3 2021 and held it in 2 quarters.
Ergoteles's Atara Biotherapeutics position peaked at $376K in Q3 2021.
109 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.